Use of HIV protease inhibitors as pharmacoenhancers

AIDS Reader

Volumn 11, Issue 2, 2001, Pages 87-98

  Moyle, G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Cytochrome P 450; Drug interactions; Pharmacokinetics; Protease inhibitors

Indexed keywords

AMPRENAVIR; CYTOCHROME P450; DELAVIRDINE; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; DOSE CALCULATION; DRUG HALF LIFE; DRUG MONITORING; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; REVIEW; SALVAGE THERAPY; TREATMENT PLANNING; VIRUS INHIBITION;

ANIMALS; ANTI-HIV AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; P-GLYCOPROTEIN; SAFETY;

EID: 0035117801     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Inhibition and induction of cytochrome P450 and the clinical implications
2. Drug-mediated inactivation of cytochrome P450
3. Characterization of human small intestinal cytochromes P-450
4. Hormonal regulation of microsomal cytochrome in rat liver and kidney
5. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
6. Cytochrome P450 3A: Ontogeny and drug disposition
7. Cytochrome p450 metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes
8. Nelfinavir: An update on its use in HIV infection
9. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
10. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
11. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
12. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
13. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture
14. Human immunodeficieney virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
15. Antiretroviral drug testing in Hiv infection: Implications for clinical management
16. Relationships between exposure of saquinavir monotherapy and antiviral response in HIV-positive patients
17. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotype guided therapy: Pharmacological data from the Viradapt study
18. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
19. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
20. Antiretroviral drug level monitoring: The next routine test in HIV management?
21. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
22. Multiple dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT-378/r) in HIV + subjects
23. The effect of ritonavir on increases in saquinavir plasma concentarion is independent of ritonavir dosage: Combined analysis of 120 subjects
24. Multiple dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir combinations in healthy volunteers
25. Pharmacokinetic interactions between ritonavir and amprenavir
26. A randomized study comparing continued indinavir (800 mg tid) vs switching to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside analogues: The BID Efficacy and Safety Trial (BEST)
27. Increased indinavir levels using twice daily ritonavir/indinavir at 100/800 mg improves virologic response even after multiple failure
28. Nelfinavir: A review of its therapeutic efficacy in HIV infection
29. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
30. Lipid abnormalities during saquinavir-soft gel based HAART
31. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
32. Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection
33. Analysis of safety data from ABT-378/ritonavir (ABT-378/r) in two phase II clinical trials
34. Efficacy of a five drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
35. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV seronegative subjects after multiple oral dosing
36. Crystalluria and urinary tract abnormalities associated with indinavir
37. Changes in renal function associated with indinavir
38. Cytochrome P450: Mechanisms of action and clinical implications
39. Genetic polymorphism of cytochrome P450: Functional consequences and possible relationship to disease and alcohol toxicity
40. P450 and human cancer
41. Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes
42. Efficacy of ABT-378/r vs nelfinavir (NFV) in antiretroviral (ARV)-naive subjects: Results of a phase III blinded randomized clinical trial
43. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24 week safety/efficacy evaluation in multiple PI experienced patients
44. The role of combinations of HIV protease inhibitors in management of persons with HIV infection